MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
Arcturus Therapeutics Holdings Operating Income 2011-2026 | ARCT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Arcturus Therapeutics Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -76.3 M | -95.7 M | -78.2 M | 12.2 M | -203 M | -71.5 M | -25.5 M | -21.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.2 M | -203 M | -70 M |
Quarterly Operating Income Arcturus Therapeutics Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.5 M | -11.6 M | - | -10.7 M | -21.1 M | -30.4 M | - | -19.3 M | -55.4 M | 14.8 M | - | -36.8 M | -22.1 M | -50.4 M | -37.6 M | -53.8 M | -53.7 M | -57.7 M | -31.1 M | -20.9 M | -10 M | -9.46 M | -10.8 M | -7.62 M | -572 K | -6.51 M | - | -4.36 M | -10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.8 M | -57.7 M | -23 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.55 | -0.28 % | $ 1.06 B |  Canada |
 |
Adagene
ADAG
|
-36 M | $ 3.91 | -2.01 % | $ 220 M |  China |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
AC Immune SA
ACIU
|
-79 M | $ 3.32 | 6.07 % | $ 229 M |  Schweiz |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
ADC Therapeutics SA
ADCT
|
-262 M | $ 4.11 | -2.61 % | $ 105 M | Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 706.03 | 0.39 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 228.06 | -1.28 % | $ 5 B |  Danmark |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 3.43 | -4.19 % | $ 7.46 B |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.51 | 1.04 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 94.86 | 4.77 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.28 | 2.86 % | $ 1.34 B | Britain |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-42.1 M | $ 1.14 | 2.7 % | $ 34.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.51 | - | $ 385 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-49.6 M | - | - | $ 521 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-181 M | $ 6.13 | 1.32 % | $ 500 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Equillium
EQ
|
-14.5 M | $ 2.15 | -7.33 % | $ 74.7 M | USA |